BR112018075201A2 - moduladores do receptor beta-3 adrenérgico úteis para o tratamento ou prevenção de distúrbios relacionados com os mesmos - Google Patents

moduladores do receptor beta-3 adrenérgico úteis para o tratamento ou prevenção de distúrbios relacionados com os mesmos

Info

Publication number
BR112018075201A2
BR112018075201A2 BR112018075201-0A BR112018075201A BR112018075201A2 BR 112018075201 A2 BR112018075201 A2 BR 112018075201A2 BR 112018075201 A BR112018075201 A BR 112018075201A BR 112018075201 A2 BR112018075201 A2 BR 112018075201A2
Authority
BR
Brazil
Prior art keywords
beta
adrenergic receptor
treating
related disorders
receptor modulators
Prior art date
Application number
BR112018075201-0A
Other languages
English (en)
Other versions
BR112018075201B1 (pt
Inventor
Tran Thuy-Anh
Do Quyen-Quyen
Ullman Brett
Original Assignee
Arena Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals, Inc. filed Critical Arena Pharmaceuticals, Inc.
Publication of BR112018075201A2 publication Critical patent/BR112018075201A2/pt
Publication of BR112018075201B1 publication Critical patent/BR112018075201B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção se refere a compostos de fórmula (ia) e composições farmacêuticas dos mesmos que modulam a atividade do receptor beta-3 adrenérgico. os compostos da presente invenção e as composições farmacêuticas dos mesmos são dirigidos a métodos úteis no tratamento de um distúrbio mediado pelo receptor beta-3 adrenérgico e condições relacionadas com os mesmos.
BR112018075201-0A 2016-06-06 2017-06-05 Compostos moduladores do receptor beta-3 adrenérgico e composição farmacêutica que os compreende, seus usos e método de preparação da referida composição BR112018075201B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662346293P 2016-06-06 2016-06-06
US62/346,293 2016-06-06
PCT/US2017/035867 WO2017214002A1 (en) 2016-06-06 2017-06-05 Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto

Publications (2)

Publication Number Publication Date
BR112018075201A2 true BR112018075201A2 (pt) 2019-03-19
BR112018075201B1 BR112018075201B1 (pt) 2024-07-09

Family

ID=

Also Published As

Publication number Publication date
KR20220025128A (ko) 2022-03-03
US10927123B2 (en) 2021-02-23
US20190284200A1 (en) 2019-09-19
TW201803877A (zh) 2018-02-01
US10662200B2 (en) 2020-05-26
EP3464292B1 (en) 2022-09-21
US20190389875A1 (en) 2019-12-26
CO2019000041A2 (es) 2019-04-30
MA44037A1 (fr) 2019-05-31
DK3464292T3 (da) 2022-10-31
CL2018003451A1 (es) 2019-02-22
CA3026024A1 (en) 2017-12-14
MX2018015124A (es) 2019-09-09
ECSP19001018A (es) 2019-02-28
UA125120C2 (uk) 2022-01-12
JP7449329B2 (ja) 2024-03-13
ES2929737T3 (es) 2022-12-01
US20200270264A1 (en) 2020-08-27
JP2020203945A (ja) 2020-12-24
MA44037B1 (fr) 2020-03-31
MA45150A (fr) 2021-05-05
MX2021014043A (es) 2022-02-21
US20190292196A1 (en) 2019-09-26
TWI752963B (zh) 2022-01-21
AU2021206809A1 (en) 2021-08-12
AU2021206809B2 (en) 2023-01-05
AR108772A1 (es) 2018-09-26
US10479797B2 (en) 2019-11-19
JP2022089984A (ja) 2022-06-16
EP3464292A1 (en) 2019-04-10
TW202237619A (zh) 2022-10-01
CN109563103B (zh) 2022-05-27
IL263148B (en) 2022-02-01
WO2017214002A1 (en) 2017-12-14
IL263148A (en) 2018-12-31
NI201800130A (es) 2019-06-13
CR20180595A (es) 2019-04-09
TWI784840B (zh) 2022-11-21
SG11201810788QA (en) 2018-12-28
PT3464292T (pt) 2022-11-15
KR20190026731A (ko) 2019-03-13
US11560386B2 (en) 2023-01-24
CN109563103A (zh) 2019-04-02
EA201892817A1 (ru) 2019-06-28
EP3464292B8 (en) 2022-10-26
IL289378A (en) 2022-02-01
KR102408272B1 (ko) 2022-06-10
AU2017278102A1 (en) 2019-01-17
NZ749202A (en) 2022-07-01
TN2018000391A1 (en) 2020-06-15
MY195982A (en) 2023-02-27
JP7083087B2 (ja) 2022-06-10
IL289378B (en) 2022-09-01
PH12018502550A1 (en) 2019-11-04
PE20190445A1 (es) 2019-03-29
JP6771246B2 (ja) 2020-10-21
JP2019518079A (ja) 2019-06-27
AU2017278102B2 (en) 2021-04-29
US20210340154A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
CL2019001711A1 (es) Composiciones y métodos para inhibir la acción de la arginasa.
BR112023021068A2 (pt) Compostos, composições e métodos para tratar câncer
BR112019006876A2 (pt) anticorpos e composições anti-lag-3
BR112017024555A2 (pt) moduladores de ccr2
BR112015029969A2 (pt) tratamento de câncer usando moduladores de isoformas quinase pi3
BR112018070747A2 (pt) átomos de silicone que contêm análogos de ivacaftor
BR112017008714A2 (pt) inibidores de bromodomínio
BR112018072663A2 (pt) moduladores da via integrada ao estresse
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
MX2020004556A (es) Moduladores de la vía de estrés integrada.
MX2020004538A (es) Moduladores de la vía de estrés integrada.
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
BR112018010720A2 (pt) agonistas do receptor de apelina e métodos de uso
BR112017021021A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
BR112015023760A2 (pt) compostos e composições terapêuticas
NO20180040A1 (en) Diaryl and arylheteroaryl urea derivatives useful for the porphylaxis and treatment of rem sleep behaviour disorder
BR112018012112A2 (pt) heteroaril-hidroxipirimidinonas como agonistas do receptor apj
BR112017021929A2 (pt) derivados de quinolina como inibidores tam rtk, composição farmacêutica compreendendo os referidos derivados e uso destes
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil
DOP2018000058A (es) Inhibidores de ezh2
BR112014022780A8 (pt) composto modulador de receptor de fígado x, composição farmacêutica que o compreende e seu uso
EA201690708A1 (ru) Ингибиторы erk и способы применения

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: ARENA PHARMACEUTICALS, INC. (US)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/06/2017, OBSERVADAS AS CONDICOES LEGAIS